Reshma Kewalramani Salary and Compensation - VERTEX PHARMACEUTICALS INC / MA CEO Salary 2025

In fiscal year 2025, Reshma Kewalramani, CEO and President of VERTEX PHARMACEUTICALS INC / MA (VRTX), received total compensation of $21.1 million.

Reshma Kewalramani's compensation breakdown includes: base salary of $1.6 million, stock awards valued at $15.0 million, non-equity incentive compensation of $4.1 million, and other compensation of $423K.

Compared to fiscal year 2024, Reshma Kewalramani's total compensation decreased 2% from $21.5 million to $21.1 million.

VERTEX PHARMACEUTICALS INC / MA (VRTX) Executive Pay 2025

VERTEX PHARMACEUTICALS INC / MA's top 6 named executive officers received combined total compensation of $59.8 million in fiscal year 2025.

The named executive officers disclosed in VERTEX PHARMACEUTICALS INC / MA's 2025 proxy statement are:Reshma Kewalramani (CEO and President) with total compensation of $21.1 million, Stuart A. Arbuckle (Former EVP & Chief Operating Officer) with total compensation of $10.0 million, Charles F. Wagner (Jr.) with total compensation of $8.2 million, Nia Tatsis (EVP & Chief Regulatory and Quality Officer) with total compensation of $7.0 million, Amit Sachdev with total compensation of $6.8 million, and Carmen Bozic with total compensation of $6.6 million.